Aspen Group Stock

Aspen Group Equity

The The Equity of Aspen Group (APZ.AX) as of Aug 6, 2026 is 545.65 M AUD. In the previous year, The Equity was 433.66 M AUD — a change of 25.83% (higher).

Equity

545.65 MAUD

YoY

25.83%

Last updated:

In 2026, Aspen Group's equity was 545.65 M AUD, a 25.83% increase from the 433.66 M AUD equity in the previous year.

Access this data via the Eulerpool API

Aspen Group Stock analysis

What does Aspen Group do? Aspen Group Ltd is a globally active pharmaceutical company headquartered in Durban, South Africa. The company's history dates back to 1850, when the first pharmacy was opened by a man named William Charles in Durban. In 1997, Aspen Group Ltd was founded, which continued William Charles' business and expanded strongly in the following years. Aspen's business model is based on the acquisition of pharmaceutical companies and their products, as well as the production of generics and branded drugs. The company operates worldwide and has offices in over 50 countries. Aspen specializes in the fields of thrombosis, anesthesia, oncology, infectious diseases, and nervous system disorders. The various divisions of Aspen include Aspen Global Commercial, Aspen Pharmacare, Aspen Nutritionals, Aspen Oss, Aspen Business Europe, and Aspen Healthcare. Aspen Global Commercial is responsible for the sale of products in various regions of the world. Aspen Pharmacare is engaged in the production and sale of generics and branded drugs. Aspen Nutritionals produces dietary supplements and baby food. Aspen Oss manufactures and distributes bone substitute materials. Aspen Business Europe is responsible for product distribution in Europe, and Aspen Healthcare operates hospitals and health centers in South Africa. Aspen offers a variety of products, including anticoagulants, anesthetics, antibiotics, cancer drugs, HIV/AIDS medications, as well as dietary supplements and baby food. In the field of thrombosis, the company offers a wide range of anticoagulants, such as the active ingredients heparin, enoxaparin, and fondaparinux. In the field of oncology, Aspen produces drugs for the treatment of breast cancer, colon cancer, and lung cancer. Aspen's products are utilized by many different customers worldwide, including government agencies, hospitals, pharmacies, and retailers. Aspen places great emphasis on the quality of its products and has implemented a quality management system to ensure that the products meet the highest standards. In recent years, there have been controversies surrounding Aspen, particularly regarding drug pricing. In 2016, Aspen was fined €5.2 million by the European Commission for charging unreasonably high prices for cancer drugs in five European countries. Aspen has denied the allegations and announced plans to appeal the decision. Despite these controversies, Aspen remains an important player in the global pharmaceutical market. The company has a wide range of products and operates in various regions of the world. Aspen is committed to improving the health and well-being of people and continuously works to develop innovative and effective medications. Aspen Group is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Aspen Group's Equity

Aspen Group's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Aspen Group's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Aspen Group's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Aspen Group's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Aspen Group’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Aspen Group stock

The Equity of Aspen Group is 545.65 M AUD in 2026.

The Equity of Aspen Group changed from 433.66 M AUD to 545.65 M AUD, representing a 25.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Aspen Group since 2006 – with annual values, charts, and detailed analysis.

The Equity's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Aspen Group historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Aspen Group

All Key Metrics — Aspen Group